# Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

> **NCT01772199** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 131 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** GSK239512
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01772199
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2016-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01772199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01772199, "Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01772199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*